MAGE-3 (161-175)

MAGE-3 (161-175) is a synthetic peptide fragment derived from the Melanoma Antigen Gene-3 (MAGE-3) protein, a member of the cancer-testis antigen family with notable expression in various tumor types but limited presence in normal tissues. As a defined sequence peptide, it is widely recognized for its role in immunological research, particularly in studies investigating tumor-associated antigens and their implications for immune recognition. The specific sequence of this peptide corresponds to residues 161 through 175 of the native MAGE-3 protein, making it a valuable tool for dissecting antigenic epitopes and understanding the molecular basis of immune responses to tumor cells. Its well-characterized structure and relevance to tumor immunology position it as an essential reagent in the fields of peptide immunology, epitope mapping, and T-cell activation studies.

Epitope Mapping: MAGE-3 (161-175) is frequently employed to map T-cell epitopes within the MAGE-3 protein, enabling researchers to identify immunogenic regions that are recognized by cytotoxic T lymphocytes. By using this peptide fragment in in vitro assays, scientists can delineate the precise amino acid residues responsible for eliciting immune responses, which is critical for characterizing tumor antigenicity and for the rational design of antigen-specific immunological experiments.

T-cell Activation Assays: The peptide serves as a functional probe in T-cell activation studies, where it is utilized to stimulate specific T-cell populations in peripheral blood mononuclear cells or engineered cell lines. Its defined sequence allows for the selective activation and expansion of MAGE-3-reactive T cells, facilitating investigations into T-cell receptor specificity, cytokine release profiles, and the mechanisms underlying tumor immune surveillance. Such studies are pivotal for elucidating the cellular dynamics that govern antitumor immunity.

Peptide-MHC Binding Studies: Investigators rely on this peptide for quantitative and qualitative analyses of peptide binding to major histocompatibility complex (MHC) molecules. By assessing the affinity and stability of the MAGE-3 (161-175) peptide with various MHC class I or II alleles, researchers can gain insights into antigen processing and presentation pathways. These findings inform the selection of optimal peptide candidates for immunological assays and contribute to a deeper understanding of immune recognition at the molecular level.

Immunogenicity Assessment: The defined nature of the MAGE-3 (161-175) sequence makes it an effective standard for evaluating the immunogenic potential of tumor-associated peptides. It is commonly used as a positive control or reference antigen in ex vivo or in vitro immunogenicity assays, such as ELISPOT or intracellular cytokine staining, to benchmark the responsiveness of immune cells against tumor-derived antigens. Such comparative analyses are essential for validating experimental systems and optimizing assay conditions.

Peptide Synthesis and Method Development: Beyond its direct applications in immunological assays, the peptide is valuable in the development and validation of peptide synthesis protocols and analytical methodologies. Its sequence complexity and defined length make it a suitable model for optimizing solid-phase peptide synthesis, purification strategies, and mass spectrometry-based identification techniques. Methodological advancements achieved using this peptide support broader research efforts in synthetic peptide chemistry and analytical biochemistry.

1. C-peptide and its C-terminal fragments improve erythrocyte deformability in type 1 diabetes patients

2. The spatiotemporal control of signalling and trafficking of the GLP-1R

3. Store-operated Ca2+ entry sustains the fertilization Ca2+ signal in pig eggs

4. Urinary Metabolites Associated with Blood Pressure on a Low-or High-Sodium Die

5. Immune-awakening Saccharomyces-inspired nanocarrier for oral target delivery to lymph and tumors